PUMA BIOTECHNOLOGY, INC.·4

Feb 14, 4:50 PM ET

Ludwig Jeffrey Jerome 4

4 · PUMA BIOTECHNOLOGY, INC. · Filed Feb 14, 2023

Insider Transaction Report

Form 4
Period: 2023-02-10
Ludwig Jeffrey Jerome
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2023-02-10+66,972125,029 total
  • Award

    Stock Option (Right to Buy)

    2023-02-10+93,02893,028 total
    Exercise: $4.39Exp: 2033-02-09Common Stock (93,028 underlying)
Footnotes (2)
  • [F1]Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Grantee's continued service with the Company through the applicable vesting date.
  • [F2]Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Optionee's continued service with the Company through the applicable vesting date.

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4